Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Rambaldi, Alessandro  [Clear All Filters]
2014
Capelli C, Pedrini O, Cassina G, Spinelli O, Salmoiraghi S, Golay J, Rambaldi A, Giussani U, Introna M. Frequent non-malignant genetic alterations occurrence in clinical grade Mesenchymal Stromal Cells expanded for Cell Therapy Protocols. Haematologica. 2014.
Pagani IS, Spinelli O, Mattarucchi E, Pirrone C, Pigni D, Amelotti E, Lilliu S, Boroni C, Intermesoli T, Giussani U, et al. Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience. 2014;1(7):510-21.
Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P, Bogani C, Fanelli T, Mannarelli C, Rosti V, et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood. 2014.
Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, et al. MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014.
Porta MGDella, Alessandrino EPaolo, Bacigalupo A, van Lint MTeresa, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood. 2014.
Lussana F, Rambaldi A. Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014065.
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
2019
Sorà F, Di Grazia C, Chiusolo P, Raiola AMaria, Bregante S, Mordini N, Olivieri A, Iori APaola, Patriarca F, Grisariu S, et al. Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2019.
Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Zugmaier G, et al. Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ. Biol Blood Marrow Transplant. 2019.
Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, et al. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.